Julie Lorent
Impact in
Papers in
-
- Breast Cancer Treatment Studies 3
- Cancer Genomics and Diagnostics 2
- Oncology 5
- Cancer-related Molecular Pathways 2
- Co-authors
- Ronald de Wit (1 shared paper)Jan Martijn Kerst (1 shared paper)Sandrine I. Marreaud (1 shared paper)Richard J Sylvester (1 shared paper)Michael Gordon Leahy (1 shared paper)Maria De Santis (1 shared paper)Thierry Gil (1 shared paper)Graham M. Mead (1 shared paper)
- Journals
- Nucleic Acids Research (2 papers)Nature Communications (2 papers)Journal of Clinical Oncology (1 paper)Infection and Immunity (1 paper)Molecular Oncology (1 paper)
- Partner nations
- SwedenCanadaUnited States
In The Last Decade
Julie Lorent
20 papers receiving 1.2k citations
Julie Lorent's Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 373
- Surgery 558
- Immunology 201
- Cancer Research 94
- Molecular Biology 307
Countries citing papers authored by Julie Lorent
This map shows the geographic impact of Julie Lorent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Lorent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Lorent more than expected).
Fields of papers citing papers by Julie Lorent
This network shows the impact of papers produced by Julie Lorent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Lorent. The network helps show where Julie Lorent may publish in the future.
Co-authors
The 25 scholars most cited alongside Julie Lorent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 Hit paper breakdown → | 2011 | 608 |
| 2 | 2016 | 132 | |
| 3 | 2019 | 64 | |
| 4 | 2017 | 56 | |
| 5 | 2015 | 44 | |
| 6 | 2019 | 41 | |
| 7 | 2018 | 40 | |
| 8 | 2011 | 31 | |
| 9 | 2019 | 31 | |
| 10 | 2014 | 24 | |
| 11 | 2018 | 24 | |
| 12 | 2018 | 23 | |
| 13 | 2020 | 22 | |
| 14 | 2022 | 21 | |
| 15 | 2017 | 18 | |
| 16 | 2015 | 17 | |
| 17 | 2009 | 11 | |
| 18 | 2016 | 11 | |
| 19 | 2023 | 6 | |
| 20 | 2024 | 2 |
About Julie Lorent
Julie Lorent is a scholar working on Cancer Research, Oncology, Immunology, Molecular Biology and Modeling and Simulation, having authored 21 papers that have together received 1.2k indexed citations. Recurring topics across this work include RNA Research and Splicing (5 papers), Breast Cancer Treatment Studies (3 papers), RNA and protein synthesis mechanisms (3 papers), Cancer Genomics and Diagnostics (2 papers), RNA modifications and cancer (2 papers), Cancer-related Molecular Pathways (2 papers), Immune Cell Function and Interaction (2 papers) and Eosinophilic Disorders and Syndromes (1 paper). The work is most often cited by research in Oncology (373 citations), Surgery (558 citations), Immunology (201 citations), Cancer Research (94 citations) and Molecular Biology (307 citations). Julie Lorent has collaborated with scholars based in Sweden, Canada and United States. Frequent co-authors include Ronald de Wit, Jan Martijn Kerst, Sandrine I. Marreaud, Richard J Sylvester, Michael Gordon Leahy, Maria De Santis, Thierry Gil, Graham M. Mead, Gedske Daugaard and Iwona Skoneczna. Their work appears in journals such as Nucleic Acids Research, Nature Communications, Journal of Clinical Oncology, Infection and Immunity and Molecular Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.